| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 12/27/2006 | CN1886366A Cyclopentyl derivates |
| 12/27/2006 | CN1886363A Amino acids with affinity for the alpha2delta-protein |
| 12/27/2006 | CN1886141A T-type calcium channel inhibitor |
| 12/27/2006 | CN1886130A Use of 2-thia-dibenzo[e, h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders |
| 12/27/2006 | CN1886127A Use of desoxypeganine for the treatment of schizophrenic psychoses |
| 12/27/2006 | CN1884550A Novel subtype CaMKII alpha3 gene and clone method, expressed protein and uses |
| 12/27/2006 | CN1884528A Nucleic acid sequence related with risperidone clinical curative effect |
| 12/27/2006 | CN1884492A Embryo stem cell for treating nerve retrograde affection and its culture medium and preparation method |
| 12/27/2006 | CN1884262A 4-amino piperidine compounds and their pharmaceutical use |
| 12/27/2006 | CN1883701A Ciliary nerves nutrilite composition having long-time stability |
| 12/27/2006 | CN1883700A Novel use of xCT protein and its encoding gene |
| 12/27/2006 | CN1883683A Mind tranquilizing tablet |
| 12/27/2006 | CN1883682A Mind tranquilizing capsule |
| 12/27/2006 | CN1883668A Dry concentrate of yellow wine and preparation method thereof |
| 12/27/2006 | CN1883646A Sobering-up agent and preparation method thereof |
| 12/27/2006 | CN1883638A Compound medicine for treating depression and method for preparing same |
| 12/27/2006 | CN1883625A Medicine for preventing dementia of middle- and old aged man |
| 12/27/2006 | CN1883615A Preparation method of sobering liquid and sobering liquid prepared thereby |
| 12/27/2006 | CN1883605A Vinegar capable of improving cerebral function |
| 12/27/2006 | CN1883592A Gel for treating rheumatism and headache and method for preparing same |
| 12/27/2006 | CN1883557A Application of 'Guizhi Gancao Longgu Muli' preparation in preparation of medicine for preventing and treating depression |
| 12/27/2006 | CN1883527A A health product of lucid ganoderma and preparation method thereof |
| 12/27/2006 | CN1883520A Hypericum perforatum L. phenolic acid and injection thereof preparation method |
| 12/27/2006 | CN1883491A Medical use of ginsenoside Rh 1 |
| 12/27/2006 | CN1883473A An enteric coated tablet of dulouxetine |
| 12/27/2006 | CN1883462A Nicotine transdermal delivery system |
| 12/27/2006 | CN1883456A Flavor-hidden pharmaceutical granule, preparation method and use thereof |
| 12/27/2006 | CN1883285A Compound sleep assistant health product |
| 12/27/2006 | CN1291995C **Tc marked dopamine transport protein developer |
| 12/27/2006 | CN1291986C Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions |
| 12/27/2006 | CN1291985C Neurotrophin production/secretion promoting agent |
| 12/27/2006 | CN1291984C 2-thio-substituted imidazole derivatives and use therof in pharmaceutical industry |
| 12/27/2006 | CN1291758C Coupling agent of CB and specific immune globulin IgG and medical use thereof |
| 12/27/2006 | CN1291745C Chinese medicinal composition for treating nervous, vascular headache, cerebral blood supply shortage and sequel of apolexy |
| 12/27/2006 | CN1291720C Non-sedating barbituric acid derivatives |
| 12/27/2006 | CN1291714C Application of phenchlobenpyrrone |
| 12/26/2006 | US7154001 Formate salt of O-desmethyl-venlafaxine |
| 12/26/2006 | US7153997 N-hydroxyphenoxyphenyl derivatives of glycine or valine, e.g., N-[3,5-Dichloro-4-(4-hydroxy-3-isopropyl-5-methylphenoxy)benzoyl]glycine; treating metabolic disorders or diseases dependent upon the expression of a T3 regulated gene |
| 12/26/2006 | US7153961 Hydrate of a benzenesulfonate salt of 4-(bis(2-methoxyethyl)amino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-[1,5-a]-pyrazolo-1,3,5-triazine; physical and chemical properties that are both physiologically acceptable and suitable for preparing reproducible pharmaceutical formulations |
| 12/26/2006 | US7153958 Farnesyl transferase inhibiting benzoheterocyclic derivatives |
| 12/26/2006 | US7153936 A peptide of at least 5 amino acids containing a unique portion of a semaphorin, and such peptide has a semaphorin binding specificity |
| 12/26/2006 | US7153882 (Aminocarbonyloxy)-benzofused ring derivatives; Alzheimer*s disease; neurodegenerative disorders |
| 12/26/2006 | US7153881 Compounds acting as melanocortin receptor ligands |
| 12/26/2006 | US7153874 For therapy and prophylaxis of of disorders mediated in full or in part by metabotropic glutamate receptor 5, including, e.g. acute, traumatic and chronic degenerative processes of the nervous system, such as Alzheimer's disease, senile dementia, Parkinson's disease, Huntington's chorea |
| 12/26/2006 | US7153873 E.g., 7-acetyl-5-tert-butylamino-6-phenyl-imidazo[2,1-b]-thiazol-7-ium chloride; treatment of pain, diarrhea, urinary incontinence, depression, and anxiety |
| 12/26/2006 | US7153865 N-type calcium channel antagonists for the treatment of pain |
| 12/26/2006 | US7153856 Orally administering N-(2-chloro-6-methylphenyl)-2-[4-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-6-ylamino]thiazole-5-carboxamide for treating cancer |
| 12/26/2006 | US7153852 Skin disorders; antiinflammatory agents; brain disorders; chronic obstructive pulmonary disease; antiarthritic agents; inflammatory bowel disorders |
| 12/26/2006 | US7153849 5HT1A antagonist; obsessive-compulsive disorder, panic attacks, generalized anxiety disorder, and social anxiety disorder |
| 12/26/2006 | US7153847 Dipeptide-substituted benzo- and dibenzocaprolactams, which inhibit beta -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease |
| 12/26/2006 | US7153837 Agent for protection of retinal neurons |
| 12/26/2006 | US7153836 Having 1-4 hydrophobic C 10-24 aliphatic, saturated or unsaturated hydrocarbon residue moieties covalently bound to a protein with a hedgehog N-terminal domain; includes auxiliary substances, detergents, stabilizers, matrix materials, suramin, heparin, anionic polysaccharides and/or sequestering agents |
| 12/26/2006 | US7153833 Therapeutic uses of SMR1 peptides |
| 12/26/2006 | US7153822 Compositions and methods for modulating connexin hemichannels |
| 12/26/2006 | US7153686 Compositions of enriched central nervous system stem cell and progenitor cell populations |
| 12/26/2006 | US7153678 Polynucleotides encoding the novel human phosphatase, RET31, and variants thereof |
| 12/26/2006 | US7153513 West nile vaccine |
| 12/21/2006 | WO2006135715A1 Benztropinamine analogs as dopamine uptake inhibitors |
| 12/21/2006 | WO2006135080A1 Thienopyrimidine derivative |
| 12/21/2006 | WO2006134955A1 1, 2-di(cyclic group)substituted benzene derivative |
| 12/21/2006 | WO2006134877A1 Injection |
| 12/21/2006 | WO2006134864A1 Solubilization preparation |
| 12/21/2006 | WO2006134600A1 Compounds useful for treating bipolar disorders |
| 12/21/2006 | WO2006134487A1 3-phenylazetidine derivatives as dopamine agonists |
| 12/21/2006 | WO2006134486A2 Alpha-(aryl-or heteroaryl-methyl)-beta piperidino propanamide compounds as orl1-receptor antagonists |
| 12/21/2006 | WO2006134341A1 Therapeutic agents |
| 12/21/2006 | WO2006133946A1 Azab i cyclo [3 . 1 . 0] hexane derivatives as dopamin d3 receptor modulators |
| 12/21/2006 | WO2006133945A1 Novel compounds |
| 12/21/2006 | WO2006133802A1 N-amide derivatives of 8-azabicyclo[3.2.1]oct-3-yl as ccr1 antagonists |
| 12/21/2006 | WO2006133652A1 Compounds, preparation process, and uses thereof used for interrupting reuptake of 5-hydroxytryptamine and norepinephrine or treating diseases such as depression et al. |
| 12/21/2006 | WO2006133588A1 ARYL UREA COMPOUNDS AS β-SECRETASE INHIBITORS |
| 12/21/2006 | WO2006133566A1 NOVEL Aß-BINDING PROTEIN AND ITS PEPTIDE DERIVATIVES AND USES THEREOF |
| 12/21/2006 | WO2006089658A3 Nk1 antagonists |
| 12/21/2006 | WO2006085121A3 Vgp peptide fragments as biomarkers for schizophrenic and bipolar disorders |
| 12/21/2006 | WO2006083673A3 Pyridine derivatives useful as inhibitors of c-jun n-terminal kinases |
| 12/21/2006 | WO2006082597A3 Crystal modification of 5-substituted-2-oxazoiidone derivative and its process thereof |
| 12/21/2006 | WO2006076569A3 Bicyclic heterocycles as cannabinoid receptor modulators |
| 12/21/2006 | WO2006058303A3 Modulators of muscarinic receptors |
| 12/21/2006 | WO2006056888A3 Glycine as a diet supplement for the treatment of health problems that result from underlying metabolic disorders |
| 12/21/2006 | WO2006018662A3 Aryl urea derivatives for treating obesity |
| 12/21/2006 | WO2005118009A3 Transdermal delivery system for treatment of cognitive disorders |
| 12/21/2006 | WO2005115367A3 Modulation of neurotransmitter activity in neurons |
| 12/21/2006 | WO2004100937B1 Combination of the analeptic modafinil and an antidepressant for the treatment of depression |
| 12/21/2006 | US20060287536 Phenyl-thiophene type vitamin d receptor modulators |
| 12/21/2006 | US20060287510 Crystallization of IGF-1 |
| 12/21/2006 | US20060287502 C3b/C4b complement receptor-like molecules and uses thereof |
| 12/21/2006 | US20060287397 Dl-hydroxy-alkyl-phenylamides having anticonvulsive activity |
| 12/21/2006 | US20060287389 Phenethanolamine derivatives for treatment of respiratory diseases |
| 12/21/2006 | US20060287383 Substance exhibiting antidepressant property |
| 12/21/2006 | US20060287374 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 12/21/2006 | US20060287353 Method for preventing or treating ischemia-or hemorrhage-induced brain damage using a macrolide compound |
| 12/21/2006 | US20060287345 Substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives as selective non-peptide delta opiod agonists with antidepressant and anxiolytic activity |
| 12/21/2006 | US20060287340 e.g. 5-(4-fluorophenyl)-N-[2-(1-methyl-2-oxo-1,7-diazaspiro[4,4]nonan-7-yl)-6-quinolinyl]-2-pyrimidinecarboxamide; melanin concentrating hormone receptor antagonist; central nervous system disorders, cardiovascular disorders and metabolic disorders |
| 12/21/2006 | US20060287338 Metalloproteinase inhibitor compounds |
| 12/21/2006 | US20060287336 S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders |
| 12/21/2006 | US20060287334 e.g. 8-(4-(4-Fluorobenzyl)-piperazin-1-yl)-3-phenylsulfonylquinoline; serotonin receptor modulator; antidepressant, anxiolytic agent, cognition activator; schizophrenia, obesity, Alzheimer's disease |
| 12/21/2006 | US20060287325 Combinations of paroxetine and 2-(r)-(4-fluoro-2-methyl-phenyl)-4-(s)-((8as)-6-oxo-hexahydro-pyrrolo'1,2-a!-pyrazin-2-yl)-piperidine-1-carboxylicacid'1-(r)-(3,5-bis-trifluoromethyl-phenyl)- |
| 12/21/2006 | US20060287310 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-butoxy]-3,4-dihydro-1H-[1,8]naphthyridin-2-one; use in the treatment of central nervous system disorders, bipolar disorder in a human; chemical synthesis |
| 12/21/2006 | US20060287309 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| 12/21/2006 | US20060287291 such as 2-Methoxy-5-methyl-N-[7-(piperazin-1-ylcarbonyl)-1-benzofuran-5-yl]benzenesulfonamide for treating disorders related to 5-HT6 receptor related disorders such as obesity, type II diabetes, anxiety, depression, panic attacks, memory/sleep/cognitive disorders, epilepsy, obsessive compulsive disorder |